Fundraising Fox
Optimeos-Logo-Web
Princeton, US · Founded 2018 · 10 employees on LinkedIn · 3 known investors
Find your way into Optimeos-Logo-Web
Sign up to see every warm intro you have to Optimeos-Logo-Web
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Optimeos-Logo-Web team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Optimeos develops a nanoparticle-based drug formulation and delivery platform (CINCs and LINCs) for complex biologics including mRNA, DNA, peptides, and proteins, targeting rare diseases, immunology, and metabolic conditions such as obesity. Its technology enables intracellular and long-acting delivery for pharmaceutical and biotech partners addressing challenges like tissue targeting and dosing profiles.
Founders & leadership
Optimeos-Logo-Web was founded in 2018 by Robert K. Prud'homme, PhD, Bob Prud'homme, Rob Pagels, and Chet Markwalter.
Board
Investors · 3
How we know: 7G BioVentures's portfolio page · Not right? Tell us
How we know: Anzu Partners's portfolio page · Not right? Tell us
How we know: Hatch BioFund's portfolio page · offering press articles · funding news · press coverage · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$4.4M disclosed across 4 rounds · 2020–2026
▶$1MraisedJun 2026 · 1 investors · BiotechnologyRule 506(b)
- Jason SmithDirector
- Shahram HejaziExecutive Officer, Director
- Robert K Prud'hommeDirector
- Benjamin DoranzDirector
- Offering amount
- $2M
- Amount sold
- $1M
- First sale
- May 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.9MraisedNov 2024 · 5 investors · BiotechnologyRule 506(b)
- Benjamin DoranzDirector
- Shahram Hejazi, PhDExecutive Officer, Director
- Jason Smith, PhDDirector
- Robert K. Prud'homme, PhDDirector
- Offering amount
- $5M
- Amount sold
- $2.9M
- First sale
- Jun 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$175KraisedJun 2021 · 4 investors · BiotechnologyRule 506(b)
- Jason Smith, PhDDirector
- Robert K Prud'homme, PhDDirector
- Shahram Hejazi, PhDExecutive Officer, Director
- Offering amount
- $300K
- Amount sold
- $175K
- First sale
- May 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$270KraisedAug 2020 · 3 investors · BiotechnologyRule 506(b)
- Robert Prud'homme, PhDDirector
- Jason Smith, PhDDirector
- Shahram Hejazi, PhDExecutive Officer, Director
- Offering amount
- $400K
- Amount sold
- $270K
- First sale
- Aug 2020
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 5 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Science Foundation | Phase II | 2023 | $1M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2022 | $287.7K |
| National Science Foundation | Phase ISTTR | 2021 | $256K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2021 | $255.4K |
| National Science Foundation | Phase ISTTR | 2019 | $225K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Optimeos-Logo-Web do?
- Optimeos develops a nanoparticle-based drug formulation and delivery platform (CINCs and LINCs) for complex biologics including mRNA, DNA, peptides, and proteins, targeting rare diseases, immunology, and metabolic conditions such as obesity. Its technology enables intracellular and long-acting delivery for pharmaceutical and biotech partners addressing challenges like tissue targeting and dosing profiles.
- Who founded Optimeos-Logo-Web?
- Optimeos-Logo-Web was founded by Robert K. Prud'homme, PhD, Bob Prud'homme, Rob Pagels, Chet Markwalter in 2018.
- Who are Optimeos-Logo-Web's investors?
- Optimeos-Logo-Web's investors include 7G BioVentures, Anzu Partners, Hatch BioFund.
- How much funding has Optimeos-Logo-Web raised?
- Optimeos-Logo-Web has disclosed $4.4M raised across 4 rounds.
- Where is Optimeos-Logo-Web headquartered?
- Optimeos-Logo-Web is headquartered in Princeton, US.